EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults

Ryan E Wiegand, Amanda B Payne, Josephine Mak, Sean Chickery, Sarah E Reese, Nicola P Klein, Shaun J Grannis, Toan C Ong, Elizabeth A K Rowley, Malini DeSilva, Kristin Dascomb, Stephanie A Irving und 26 weitere

JAMA Internal Medicine · 2026

DOI: 10.1001/jamainternmed.2026.1936 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Internal Medicine, 2026. Verfasst von Ryan E Wiegand und 37 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. Hauptthemen laut MEDLINE: COVID-19 Vaccines, Vaccine Efficacy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Vaccine effectiveness (VE) estimates are needed to monitor the effect of updated COVID-19 vaccinations.

Objective

To assess the effectiveness of 2024-2025 COVID-19 vaccines against medically attended COVID-19 among adults 18 years and older in the US. Design, Setting, and Participants This case-control study with a test-negative design included patient encounters with a COVID-19–like illness discharge diagnosis code and a molecular or antigen SARS-CoV-2 test within 10 days before to 3 days after the encounter date, from September 5, 2024, to September 2, 2025. Encounters were captured in VISION (Virtual SARS-CoV-2, Influenza, and Other Respiratory Viruses Network), a multisite, electronic medical record–based network of health care systems, including 381 emergency department/urgent care (ED/UC) departments and 246 hospitals in 6 states. Exposure Vaccination with a 2024-2025 COVID-19 vaccine formulation (approved by the US Food and Drug Administration in August 2024) in the previous 7 to 299 days. Main Outcomes and Measures Outcomes were COVID-19–associated ED/UC encounters, COVID-19–associated hospitalization, and COVID-19–associated critical illness (hospitalization with an intensive care unit admission or in-hospital death). Encounters with a positive molecular or antigen SARS-CoV-2 test result were classified as cases, and encounters with a negative molecular SARS-CoV-2 test result were classified as controls. The odds of 2024-2025 COVID-19 vaccination were compared among cases and controls, adjusting for confounders, with estimated VE calculated as (1 − adjusted odds ratio) × 100%.

Results

In 333 262 eligible ED/UC encounters (median [IQR] age of patients, 54 [35-72] years; 60% female) and 97 663 eligible hospitalizations among immunocompetent adults 18 years and older (median [IQR] age of patients, 72 [59-81] years; 53% female), estimated VE was 26% (95% CI, 23%-29%) against COVID-19–associated ED/UC encounters, 35% (95% CI, 30%-40%) against COVID-19–associated hospitalization, and 41% (95% CI, 28%-51%) against COVID-19–associated critical illness 7 to 299 days after vaccination. Among immunocompetent adults 65 years and older (122 663 ED/UC encounters and 63 958 hospitalizations), estimated VE was 26% (95% CI, 22%-30%) against COVID-19–associated ED/UC encounters, 35% (95% CI, 29%-40%) against COVID-19–associated hospitalization, and 41% (95% CI, 28%-52%) against COVID-19–associated critical illness 7 to 299 days after vaccination. Among 32 629 hospitalizations in immunocompromised adults 18 years and older, estimated VE against COVID-19–associated hospitalization was 24% (95% CI, 13%-34%). VE estimates waned with more time since vaccination. Conclusions and Relevance In this test-negative case-control study, 2024-2025 COVID-19 vaccination was associated with reduced likelihood of medically attended COVID-19–associated outcomes among immunocompetent and immunocompromised adults, highlighting the importance of adults receiving recommended COVID-19 vaccinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesVaccine EfficacyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCase-Control StudiesCOVID-19HospitalizationSARS-CoV-2United StatesVaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Westat, Bethesda, Maryland.
  • Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland.
  • Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana.
  • Department of Family Medicine, School of Medicine, Indiana University, Indianapolis.
  • School of Medicine, University of Colorado Anschutz Medical Campus, Aurora.

Zitieren

APA

Wiegand, R. E., Payne, A. B., Mak, J., Chickery, S., Reese, S. E., Klein, N. P., Grannis, S. J., Ong, T. C., Rowley, E. A. K., DeSilva, M., Dascomb, K., Irving, S. A., Zerbo, O., Hansen, J. R., Block, L., Jacobson, K. B., Dixon, B. E., Rogerson, C. M., Duszynski, T. J., …, & Link-Gelles, R. (2026). Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2026.1936

Vancouver

Wiegand RE, Payne AB, Mak J, Chickery S, Reese SE, Klein NP, et al. Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults. JAMA Internal Medicine. 2026. doi:10.1001/jamainternmed.2026.1936

BibTeX
@article{Wiegand2026,
  author = {Wiegand, Ryan E and Payne, Amanda B and Mak, Josephine and Chickery, Sean and Reese, Sarah E and Klein, Nicola P and Grannis, Shaun J and Ong, Toan C and Rowley, Elizabeth A K and DeSilva, Malini and Dascomb, Kristin and Irving, Stephanie A and Zerbo, Ousseny and Hansen, John R and Block, Lawrence and Jacobson, Karen B and Dixon, Brian E and Rogerson, Colin M and Duszynski, Thomas J and Fadel, William F and Barron, Michelle A and Mayer, David and Chavez, Catia and Yang, Duck-Hye and Ball, Sarah W and McEvoy, Charlene E and Akinsete, Omobosola O and Sheffield, Tamara and Bride, Daniel and Arndorfer, Julie and Van Otterloo, Joshua and Naleway, Allison L and Natarajan, Karthik and Najdowski, Morgan and Ciesla, Allison Avrich and Kautz, Amber and DeCuir, Jennifer and Link-Gelles, Ruth},
  title = {Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults},
  journal = {JAMA Internal Medicine},
  year = {2026},
  doi = {10.1001/jamainternmed.2026.1936}
}
Kostenlos starten →